XtalPi Secures Over $400 Million AI Drug Discovery Deal Targeting Challenging GPCR Target

According to the agreement,The partner will pay an upfront payment to XtalPi and bear all early-stage research and development costs., XtalPi will also receive preclinical, clinical, and commercial milestone payments, as well as future sales royalties,The project's potential total value exceeds US$400 million. This kind ofRecent R&D Revenue Is Deeply Tied to the Long-Term Pipeline Asset Valuecollaboration model, which not only effectively reduces the costs and risks for XtalPi in participating in the R&D of high-barrier targets, but also secures the high-upside return potential of blockbuster drugs. This collaboration not only demonstrates the profound trust that leading pharmaceutical companies place in XtalPi’s R&D capabilities, but also further validates the competitive advantages and sustainable growth potential of the XtalPi platform in tackling undruggable and high-value targets.

Small Molecules Targeting Complex GPCRs

"The Dilemma of 'Undruggable' Targets"

The GPCR targets central to this collaboration exhibit dynamic equilibrium among multiple subtypes, and their native binding pockets are extremely difficult for small molecules to target with precision. There are no publicly reported co-crystal structures of small molecules bound to these targets worldwide. Faced with such “structural blind spots,” traditional high-throughput screening (HTS) struggles to simultaneously optimize core parameters—including potency, selectivity, and pharmacokinetic properties—and generate competitive molecular candidates. All existing small-molecule pipeline projects currently under investigation remain in early-stage clinical development.

Addressing this structural biology challenge, XtalPi leveraged its advanced computational drug discovery platform to significantly enhance the efficiency and accuracy of hit identification, achieving a transformation from traditional “needle-in-a-haystack” approaches to “intelligent navigation,” thereby demonstrating exceptional innovative breakthroughs and delivery capabilities in the client’s lead optimization project.

The XtalPi team successfully “decoded” the key conformations of this target using multi-scale enhanced sampling simulation techniques, and adopted a multi-conformation collaborative screening strategy to significantly increase the likelihood of discovering highly potent active molecules. In lead optimization projects, leveraging advanced quantum physics models and AI algorithms, XtalPi conducted efficient virtual screening of a commercial compound library comprising hundreds of millions of entries, and accurately predicted molecular affinity using the XFEP free energy perturbation platform.Significantly improved the hit rate of molecular screening, earning high recognition from clients and directly facilitating and accelerating the signing of this strategic partnership.。

Automation and AI Engine:

Reshaping the New Drug R&D Paradigm at Scale

Upon entering into comprehensive collaboration, XtalPi will leverage its structure-based rational drug design platform that integrates quantum physics with AI, combined with large-scale automated chemical synthesis, to fully empower rapid DMTA (Design-Make-Test-Analyze) cycles. Under the orchestration of Multi-Agent systems, its automated laboratories will continuously generate candidate molecules featuring potent activity, novel structures, and ideal ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties. This approach significantly expands the druggable chemical space and shortens R&D timelines. The strategic partnership between the two parties is poised to accelerate the translation of cutting-edge computational biology breakthroughs into tangible pipeline assets that benefit patients worldwide.

Wen Shuhao, Chairman of the Board of Directors of XtalPi, stated:“The achievement of this strategic partnership marks another real-world validation of XtalPi’s ‘AI + Robotics’ underlying R&D system on the global stage of top-tier biopharmaceutical innovation. We will continue to leverage XtalPi’s platform advantages to build a ‘new infrastructure’ that empowers global innovative drug development, transforming biological challenges—both formidable and of significant market value—into high-potential pipeline assets. We look forward to our collaboration successfully tackling major oral therapies in the field of metabolism, delivering more convenient and efficient treatment solutions to patients worldwide.”